Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

被引：2

作者：

Pipe, Steven ^{[1
]}

Collins, Peter ^{[2
]}

Dhalluin, Christophe ^{[3
]}

Kenet, Gili ^{[4
,5
]}

Schmitt, Christophe ^{[3
]}

Buri, Muriel ^{[3
]}

Jimenez-Yuste, Victor ^{[6
]}

Peyvandi, Flora ^{[7
,8
]}

Young, Guy ^{[9
]}

Oldenburg, Johannes ^{[10
]}

Mancuso, Maria Elisa ^{[11
,12
]}

Kavakli, Kaan ^{[13
]}

Kiialainen, Anna ^{[3
]}

Chang, Tiffany ^{[14
]}

Lehle, Michaela ^{[3
]}

Niggli, Markus ^{[3
]}

Fijnvandraat, Karin ^{[15
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cardiff Univ, Sch Med, Cardiff, Wales

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Autonoma Madrid, La Paz Univ Hosp Idi Paz, Madrid, Spain

[7] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy

[8] Univ Milan, Milan, Italy

[9] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[10] Univ Bonn, Bonn, Germany

[11] IRCCS Humanitas Res Hosp, Rozzano, Italy

[12] Humanitas Univ, Rozzano, Italy

[13] Ege Univ, Fac Med, Childrens Hosp, Izmir, Turkiye

[14] Spark Therapeut Inc, San Francisco, CA USA

[15] Univ Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177963

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Niggli, Markus
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 99
[2] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
BLOOD, 2022, 140
[3] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
Pipe, S. W.
Collins, P.
Dhalluin, C.
Kenet, G.
Schmitt, C.
Buri, M.
Jimenez-Yuste, V.
Peyvandi, F.
Young, G.
Oldenburg, J.
Mancuso, M. E.
Kavakli, K.
Kiialainen, A.
Niggli, M.
Chang, T.
Lehle, M.
Fijnvandraat, K.
HAEMOPHILIA, 2024, 30 : 24 - 25
[4] FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A
Young, Guy
Eakle, Katherine
Lim, Elise
Wang, Michael
BLOOD, 2024, 144 : 2589 - 2590
[5] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY
Negrier, C.
Mahlangu, J.
Lehle, M.
Chowdary, P.
Catalani, O.
Jimenez-Yuste, V.
Beckermann, B. M.
Schmitt, C.
Hermans, C.
Ventriglia, G.
Windyga, J.
Kiialainen, A.
d'Oiron, R.
Moorehead, P.
Teodoro, V.
Shapiro, A.
Oldenburg, J.
HAEMOPHILIA, 2022, 28 : 20 - 21
[6] EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
ElisaMancuso, Maria
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
PEDIATRIC BLOOD & CANCER, 2023, 70 : S7 - S7
[7] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
Shima, Midori
JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
[8] HAVEN 7, Primary Analysis: Infants benefit from early Prophylaxis with Emicizumab
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2024, 51 (03) : 201 - 201
[9] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Robert G.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
[10] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Bob G. G.
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580

← 1 2 3 4 5 →